SCHEMBL5636394

SCHEMBL5636394

c1cc2c3c(c1)[C@H]1CNCC[C@H]1N3CCCO2

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 14/20 0.60
HTR2A P28223 9/20 0.60
HTR2B P41595 4/20 0.60
HTR1A P08908 1/20 0.39
DRD4 P21917 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
DRD2 P14416 4/20 0.39
ADRB1 P08588 1/20 0.32
EED O75530 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636506 1.00 HTR2C (0.60) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5636025 0.92 HTR2C (0.56) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5635000 0.92 HTR2C (0.56) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5636776 0.89 HTR2C (0.52) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5636602 0.83 HTR2C (0.48) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5637404 0.82 HTR2C (0.48) HTR2CHTR2AHTR2B
SCHEMBL5637076 0.81 HTR2C (0.44) HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL5635163 0.81 HTR2C (0.65) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5636261 0.80 HTR2C (0.52) HTR2CHTR2AHTR2BHTR1ADRD4
SCHEMBL5636282 0.78 HTR2C (0.46) HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed